{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5"},{"groupId":"OG001","value":"19.1"},{"groupId":"OG002","value":"20.2"},{"groupId":"OG003","value":"3.7"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"TEAEs Leading to Treatment Discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.1"},{"groupId":"OG001","value":"39.4"},{"groupId":"OG002","value":"34.0"},{"groupId":"OG003","value":"3.7"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"title":"TEAEs Leading to Dose Reduction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.9"},{"groupId":"OG001","value":"68.1"},{"groupId":"OG002","value":"66.0"},{"groupId":"OG003","value":"7.4"},{"groupId":"OG004","value":"11.8"},{"groupId":"OG005","value":"5.9"}]}],"title":"TEAEs Leading to Dose Interruption"}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"94"},{"groupId":"OG002","value":"94"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"17"}],"units":"Participants"}],"description":"An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"},{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG003","title":"Close-out Period: Cohort A: Ponatinib 45 mg"},{"description":"Ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG004","title":"Close-out Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG005","title":"Close-out Period: Cohort C: Ponatinib 15 mg"}],"paramType":"NUMBER","populationDescription":"Safety Population included all participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to approximately 9.8 years","title":"Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption","type":"SECONDARY","unitOfMeasure":"percentage of participants"}